Express Pharma

Cambridge Univ appoints Hilleman Labs’ Dr Ankur Mutreja


He was appointed at the University of Cambridge under the DBT Cambridge Lectureship programme

Dr Ankur Mutreja

Hilleman Laboratories has announced Dr Ankur Mutreja’s appointment at the University of Cambridge under the DBT Cambridge Lectureship programme. In partnership with the Government of India’s (GoI’s) Department of Biotechnology (DBT), the University invited applications for five fixed-term, research-oriented University Lectureships to strengthen the University’s strategic relationship with Indian research institutions and enhance academic, research and translational capacities of India and the UK.

Mutreja, who has been with Hilleman Laboratories, leading the company’s ETEC vaccine project is elated on being selected for this highly coveted role. Expressing his views, Mutreja, Project Lead Hilleman Laboratories said, “I am humbled to receive this honour and grateful to the University of Cambridge and the Department of Biotechnology, GoI for considering me for this prestigious position. I would also like to express my gratitude to Hilleman Laboratories for providing me a stimulating and highly motivating environment to enhance my knowledge and expertise through advanced research. I look forward to my continued association with the organisation.”

Dr Davinder Gill, Chief Executive Officer, Hilleman Laboratories said, “We are proud of Mutreja’s accomplishment and extend our support through his five-year stint at the University of Cambridge.” Highlighting this as a significant opportunity for Hilleman Laboratories, Gill added, “This presents a unique engagement platform wherein we aim to foster strategic alliances across the UK and Europe.”

EP News BureauMumbai

Comments are closed.